论文部分内容阅读
目的观察益赛普联合甲氨蝶呤(MTX)短期治疗银屑病关节炎(PsA)的临床疗效与安全性。方法对入院前采用传统治疗方案(非甾体类抗炎药联合甲氨蝶呤或其他免疫抑制剂)治疗至少3个月临床未缓解的18例患者,入院后给予益赛普25mg,2次/周,皮下注射,给予甲氨蝶呤10-15mg,1次/周,12周后停用,观察患者治疗前后的临床症状、炎性实验室指标的改善情况及药物安全性。结果 18例患者关节压痛数、关节肿胀数、银屑病的皮损面积和严重度指数(PASI)均明显降低,血沉及C反应蛋白亦明显下降,治疗前后比较差异有统计学意义(P<0.05)。18例患者均未见严重不良反应发生。结论益赛普联合甲氨蝶呤短期治疗PsA能明显改善症状,减轻皮损,并且具有良好的安全性和耐受性。
Objective To observe the clinical efficacy and safety of imatinib combined with methotrexate (MTX) in short-term treatment of psoriatic arthritis (PsA). Methods 18 patients who were treated with traditional treatment (non-steroidal anti-inflammatory drugs combined with methotrexate or other immunosuppressive agents) and were not relieved for at least 3 months before admission were given 25 mg of ilexopril twice a day / Week, subcutaneous injection of methotrexate given 10-15mg, 1 / week, 12 weeks after the withdrawal of patients before and after treatment to observe the clinical symptoms and inflammatory laboratory indicators to improve the situation and drug safety. Results The number of joint tenderness, swollen joint, lesion area and severity index (PASI) of psoriasis in 18 patients were significantly decreased, and the erythrocyte sedimentation rate and C-reactive protein were also significantly decreased. The difference was statistically significant before and after treatment (P < 0.05). None of the 18 patients experienced serious adverse reactions. Conclusion The short-term treatment of Isphase combined with methotrexate can significantly improve the symptoms of PsA, reduce skin lesions, and has good safety and tolerability.